XML 27 R16.htm IDEA: XBRL DOCUMENT
v3.25.2

EARNINGS (LOSS) PER SHARE | 6 Months Ended
--- | ---
Jun. 30, 2025
Earnings Per Share [Abstract] |
EARNINGS (LOSS) PER SHARE | NOTE 8 – EARNINGS (LOSS) PER SHARE Basic earnings (loss) per common share (“EPS”) is based on the weighted average number of common shares outstanding during each period presented. Shares of unissued vested restricted stock units (“RSUs”) and restricted stock awards (“RSAs”) are included in our calculation of basic weighted average common shares outstanding. Unvested RSUs and RSAs, convertible securities, warrants and options to purchase common stock are included as common stock equivalents only when dilutive. Potential common stock equivalents are excluded from diluted earnings per share when the effects would be antidilutive. The Company follows the provisions of ASC 260, Diluted Earnings per Share. In computing diluted EPS, basic EPS is adjusted for the assumed issuance of all potentially dilutive securities. The dilutive effect of call options, warrants and share-based payment awards is calculated using the “treasury stock method,” which assumes that the “proceeds” from the exercise of these instruments are used to purchase common shares at the average market price for the period. The dilutive effect of traditional convertible debt and convertible preferred stock is calculated using the “if-converted method.” Under the if-converted method, securities are assumed to be converted at the beginning of the period, and the resulting common shares are included in the denominator of the diluted EPS calculation for the entire period being presented. The following table sets forth the computation of basic and diluted earnings (loss) per share: SCHEDULE OF BASIC AND DILUTED EARNINGS (LOSS) PER SHARE
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Numerator: |  |  |  |  |  |  |  |  |  |  |  |
Net loss attributable to LifeMD, Inc. common stockholders - basic |  | $ | (2,851,436 | ) |  | $ | (7,652,202 | ) |  | $ | (2,243,195 | ) |  | $ | (15,197,120 | )
Adjustment |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Net loss attributable to LifeMD, Inc. common stockholders - diluted |  | $ | (2,851,436 | ) |  | $ | (7,652,202 | ) |  | $ | (2,243,195 | ) |  | $ | (15,197,120 | )
Denominator: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average number of common shares outstanding - basic |  |  | 44,401,531 |  |  |  | 41,296,042 |  |  |  | 43,772,151 |  |  |  | 40,269,139 |
Adjustment for the potential dilutive common shares |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Weighted average number of common shares outstanding - diluted |  |  | 44,401,531 |  |  |  | 41,296,042 |  |  |  | 43,772,151 |  |  |  | 40,269,139 |
Basic loss per share attributable to LifeMD, Inc. common stockholders |  | $ | (0.06 | ) |  | $ | (0.19 | ) |  | $ | (0.05 | ) |  | $ | (0.38 | )
Diluted loss per share attributable to LifeMD, Inc. common stockholders |  | $ | (0.06 | ) |  | $ | (0.19 | ) |  | $ | (0.05 | ) |  | $ | (0.38 | )
Basic loss per share is the same as diluted net loss per share attributable to common stockholders for the three and six months ended June 30, 2025 and 2024, because the inclusion of potential shares of common stock would have been anti-dilutive. The following table discloses the securities that were not included in the computation of diluted net earnings (loss) per share as their inclusion would have been anti-dilutive: SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
RSUs and RSAs |  |  | 1,933,014 |  |  |  | 2,279,750 |  |  |  | 1,582,467 |  |  |  | 2,296,125 |
Stock options |  |  | 437,544 |  |  |  | 1,527,000 |  |  |  | 424,941 |  |  |  | 1,843,375 |
Warrants |  |  | 1,024,809 |  |  |  | 1,743,730 |  |  |  | 971,327 |  |  |  | 2,068,419 |
Convertible long-term debt |  |  | 671,141 |  |  |  | 671,141 |  |  |  | 671,141 |  |  |  | 671,141 |
Total |  |  | 4,066,508 |  |  |  | 6,221,621 |  |  |  | 3,649,876 |  |  |  | 6,879,060 |

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration